Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support

Stock Track

07/06

SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.

The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.

Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1171774118"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171774118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171774118?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171774118","market":"sg","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support","media":"Stock Track","content":"<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-06 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1171774118","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171774118","pubTimestamp":1783302443,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票轨迹|SBP集团盘中大涨5.49%药物管线进展及政策利好支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}